Mahshid Gazorpak

Mahshid Gazorpak

Auto-generated profile, based on publicly available information

Mahshid Gazorpak

Laboratory of Epigenetics and Neuroendocrinology, Institute for Neuroscience, Department of Health Science and Technology, ETH Zürich

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MGMahshid Gazorpak
Mahshid Gazorpak
KHKarina M. Hugentobler
Karina M. Hugentobler
DPDominique Paul
Dominique Paul
PGPierre-Luc Germain
Pierre-Luc Germain
MKMiriam Kretschmer
Miriam Kretschmer
KGKatharina Gapp
Katharina Gapp
Counteracting the overactivation of glucocorticoid receptors (GR) is an important therapeutic goal in stress-related psychiatry and beyond. The only clinically approved GR antagonist lacks selectivity and induces unwanted side effects. To complement existing tools of small-molecule-based inhibitors, we present a highly potent, catalytically-driven GR degrader, KH-103, based on proteolysis-targeting chimera technology. This selective degrader enables immediate and reversible GR depletion that is independent of genetic manipulation and circumvents transcriptional adaptations to inhibition. KH-103 achieves passive inhibition, preventing agonistic induction of gene expression, and significantly averts the GR’s genomic effects compared to two currently available inhibitors. Application in primary-neuron cultures revealed the dependency of a glucocorticoid-induced increase in spontaneous calcium activity on GR. Finally, we present a proof of concept for application in vivo. KH-103 opens opportunities for a more lucid interpretation of GR functions with translational potential.

21 May 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
KFKarina M. Freitag
Karina M. Freitag
RSRobin Scheuplein
Robin Scheuplein
COChiara Orlacchio
Chiara Orlacchio
VAViola Ansuinelli
Viola Ansuinelli
TFTommaso Fava
Tommaso Fava
KGKatharina Gapp
Katharina Gapp
Cancer cell dormancy is a key contributor to therapy resistance and disease relapse. The glucocorticoid receptor (GR), a major mediator of stress hormone signaling, has emerged as a central regulator of dormancy in non-lymphoid solid tumors, particularly lung cancer. However, systemic GR inhibition or degradation using conventional Proteolysis Targeting Chimeras (PROTACs) risks widespread on-target toxicity due to their constitutive activity. We hypothesized that integrating photoswitchable elements into PROTACs, termed photoPROTACs, would enable wavelength-specific, spatiotemporally precise modulation of GR degradation and dormancy-associated signaling pathways. Here, we synthesized a diverse series of photoPROTACs incorporating photoswitchable arylazotriazole or arylazopyrazole scaffolds, including previously unreported (OEt) 2 - and (NMe 2 ) 2 -substituted photoswitches. Arylazopyrazole-based GR photoPROTACs bearing Me 2 - and (OEt) 2 substituents exhibited near-quantitative photoisomerization (95% Z- isomer; 89 to 92% E- isomer), no photobleaching, and thermal half-lives in the range of 3 to 12.2 d in dimethyl sulfoxide (DMSO). Among them, KH-5-306 and KH-5-309 induced potent, specific, and reversible GR degradation in their thermodynamically stable E- isomeric form at low nanomolar concentrations, with markedly reduced activity in the Z- isomeric state. Transcriptomic profiling showed that E- KH-5-309 disrupts GR-driven dormancy-associated gene expression programs in a non–small cell lung cancer (NSCLC) model, while the Z- isomer remains functionally inert. Our findings establish a framework for the rational design of photoswitchable PROTACs beyond GR and demonstrate their potential to achieve spatiotemporal control of stress hormone receptor signaling, enabling mechanistic insights into GR function and the targeted disruption of cancer cell dormancy.

18 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMahshid Gazorpak
Mahshid Gazorpak
KHKarina M. Hugentobler
Karina M. Hugentobler
DPDominique Paul
Dominique Paul
PGPierre-Luc Germain
Pierre-Luc Germain
KMKei Matthis
Kei Matthis
KGKatharina Gapp
Katharina Gapp
Counteracting the overactivation of glucocorticoid receptors (GR) is an important therapeutic goal in stress-related psychiatry and beyond. The only clinically approved GR antagonist lacks selectivity and induces unwanted side effects. To complement existing tools of small-molecule-based inhibitors, we present a highly potent, novel catalytically-driven GR degrader, KH-103, based on proteolysis-targeting chimera technology. This selective degrader enables immediate and reversible GR depletion that is independent of genetic manipulation and circumvents transcriptional adaptations to inhibition. KH-103 achieves passive inhibition, preventing agonistic induction of gene expression, and significantly averts the GR’s genomic effects compared to two currently available inhibitors. Application in primary-neuron cultures revealed the dependency of a glucocorticoid-induced increase in spontaneous calcium activity on GR. Finally, we present a proof of concept for application in-vivo. KH-103 opens opportunities for a more lucid interpretation of GR functions with translational potential.